Navigation Links
NVHR Responds to New York Times Article on Hepatitis C Testing
Date:7/22/2010

WASHINGTON, July 22 /PRNewswire-USNewswire/ -- In response to today's New York Times article, "Hope against Hepatitis C," Andrew Muir, M.D., M.H.S., Director, Gastroenterology/Hepatology Research, Duke Clinical Research Institute and Steering Committee Member of the National Viral Hepatitis Roundtable (NVHR) released the following statement:

"Today's New York Times article details potential promising new drug therapies that could significantly improve the way we treat individuals infected with hepatitis C.  Regrettably, the article suggests that expanded screening for hepatitis C may not be warranted.  This approach is wrong and contrary to the direction in which we should and must move our health care system, particularly through improved access to care under health care reform.  More than 5 million Americans are estimated to be infected with viral hepatitis B or C – and most are unaware they are infected as there are often few symptoms.  Our health care system misses most infected individuals, who only learn that they have hepatitis C once they have progressed to liver cancer, cirrhosis, or liver failure.  At that juncture, treatment options are limited and success rates are lower.

"Precisely because we do not know which individuals with hepatitis C will advance to these terrible diseases, it is critical that our public health infrastructure be modernized to achieve early detection of new infections and also to screen for individuals within specific risk groups, such as baby boomers and disproportionately affected populations.  Once individuals are aware of their status, they will be empowered with this information, not only to make treatment choices, but also lifestyle choices to decrease their likelihood of disease progression and not to spread this infectious disease to others.  In our current health care system, there are far too few options for diagnosis, care, and treatment.  Unless or until the health care system provides access to all persons in need of hepatitis C treatment, it is important for the pharmaceutical industry to provide comprehensive compassionate care programs for those who are un/under insured.

"We can't prevent or treat what we don't know, which is why screening is critical.  Access to screening would capture more infected individuals who can respond favorably to early intervention, reduce transmission, avoid needless medical expenses, and ultimately save thousands of lives annually."

NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from chronic viral hepatitis that afflicts more than 5 million Americans. www.nvhr.org


'/>"/>
SOURCE National Viral Hepatitis Roundtable
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Responds to FDA Advisory Committee Recommendation
2. Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA
3. New Science Education Program Responds to Presidents Call to Help Young People Excel in Science
4. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
5. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
6. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
7. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
8. Endologix Responds to Alleged Patent Infringement
9. EPSScentral Responds to Pandemic Alert
10. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
11. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a large selection ... by professional organic farmers and nurseries according to Sales Manager Joe Steele who says, ... Our goal is to offer wholesale level pricing and ultra-fast shipping for growers of ...
(Date:4/28/2016)... , ... April 28, 2016 , ... In 2011, TIME ... in the emerging field of biomechatronics, technology that marries human physiology with electromechanics. He ... Lab. He is also the Founder of BionX , a leader in the ...
(Date:4/28/2016)... Chicago, Illinois (PRWEB) , ... ... ... Inc., the leading provider of enterprise Data Center Infrastructure Management solutions, announces ... 14.5 focuses on feature enhancements in the area of capacity management and ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... One way ... say anything.” This is unfortunately true. But we toss the baby out with the ... single-page brief provides tips for identifying higher-quality studies and otherwise making better use of ...
(Date:4/28/2016)... ... 28, 2016 , ... USA Medical Card reminds us that May is National Stroke Awareness Month. ... fourth leading cause of death in the United States; someone has one every 40 seconds. ... in individuals under 65 years old. A stroke is when blood flow to the ...
Breaking Medicine News(10 mins):